January 18, 2022

Mitsubishi Tanabe Pharma Corporation Enters into
Exclusive License Agreement with ADC Therapeutics
to Develop and Commercialize Loncastuximab Tesirine,
Anti-CD19 Antibody Drug Conjugate (“ADC”), for Cancer in Japan- Collaboration Reflects MTPC’s Strong Commitment to Precision Medicine asContemplated under the VISION30 and Its Understanding of Antibody Drug
Conjugate Technology- MTPC to pay $30M in Upfront Payment and Potentially Over $200M in Additional
Milestone Payments
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President &Representative Director: Hiroaki Ueno; “MTPC”) announced that it entered into anexclusive license agreement with ADC Therapeutics SA. (Head Office: Epalinges,Switzerland;

CEO,ChrisMartin;

NYSE:ADCT)

forthedevelopmentandcommercialization of Loncastuximab tesirine, their first-in-class anti-CD19 antibody
drug conjugate. This agreement grants to MTPC exclusive rights to develop andcommercialize Loncastuximab tesirine for all hematologic and solid tumor indicationsin Japan.
MTPC has been conducting research and development of some antibody drug
conjugate projects for the treatment of cancer at Tanabe Research Laboratories
U.S.A., Inc. (TRL) in San Diego, CA. MTPC is very delighted to collaborate on thedevelopment of Loncastuximab tesirine with ADCT, a leading biotechnology
company focusing on the research and development of novel ADC drugs in theoncology field.

MTPC has started a new Journey through this collaboration withADCT.
As part of MTPCʼs growth strategy to realize “VISION 30”, which was formulated as
its company vision for 2030, MTPC is focusing on “Precision Medicine” by identifying
patients with high efficacy and safety in advance and delivering drugs with hightreatment satisfaction to the optimal patients. MTPC believes that the developmentof this product in Japan is a big step toward the realization of “Precision Medicine”,
including a molecular targeted approach.
Under the terms of the agreement, MTPC will pay ADCT a one-time upfront payment
1 / 3

of $30 million and up to an additional $205 million if certain development andcommercial milestones are achieved. MTPC will also pay to ADCT royalties based on
net sales of the product in Japan. Furthermore, MTPC will have the right toparticipate in any global clinical studies of the product by bearing the development
cost in Japan. ADCT continuously retains all rights to develop and commercialize
the product outside Japan.
MTPC is engaged in R&D activities to address unmet medical needs.

MTPC will

yield results of this product as early as possible and contribute to the well-being ofpatients suffering from cancer in Japan.
Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department
Media contacts: TEL: +81 6 6205 5119

■About Loncastuximab tesirine
Loncastuximab tesirine is a first-in-class anti-CD19 antibody drug conjugate. CD19
protein is specifically expressed on the majority of B cells that affect some types of
non-Hodgkin lymphoma (NHL). Loncastuximab tesirine binds to CD19 and kills
these B cells through the delivery of anticancer agents as warhead, thereby
reducing their impact on normal cells.

Loncastuximab tesirine is being developedby ADCT and under investigation for a variety of types of NHL.

Loncastuximab

tesirine, which is being developed by ADCT for the treatment of several types ofNHL, was granted accelerated approval in the U.S. in April 2021 and is alreadymarketed under the brand name ZYNLONTA®.

■About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company
improving the lives of those affected by cancer with its next-generation, targeted
antibody drug conjugates (ADCs). The Company is advancing its proprietary PBDbased ADC technology to transform the treatment paradigm for patients with2 / 3

hematologic malignancies and solid tumors.
ADC Therapeuticsʼ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) isapproved by the FDA for the treatment of relapsed or refractory diffuse large B-celllymphoma after two or more lines of systemic therapy. ZYNLONTA is also indevelopment in combination with other agents. Cami (camidanlumab tesirine) isbeing evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. Inaddition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoingclinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operationsin London, the San Francisco Bay Area and New Jersey.
For more information, please visit https://adctherapeutics.com/ and follow theCompany on Twitter and LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

3 / 3